The evaluation of the effectiveness of anti-ICOS ADCs in patient-derived xenografts from individuals with SS and angioimmunoblastic T-cell lymphoma yielded promising results [40]. This evidence concerns the gene ICOS and angioimmunoblastic T-cell lymphoma.